Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer. ADCETRIS The company’s marketed product ADCETRIS, or brentuximab vedotin, is approved by the United States Food and Drug Administration (FDA) for three indications, including various settings for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL). ADCETRIS is commercially available in approximately 60 countries worldwide, including in the United States, Canada, members of the European Union and Japan. ADCETRIS is an ADC (antibody-drug conjugate) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a proprietary microtubule disrupting agent, monomethyl auristatin E (MMAE). ADCETRIS employs a linker system that is designed to be stable in the bloodstream and to release MMAE upon internalization into CD30-expressing cells. The company is collaborating with Takeda Pharmaceutical Company Limited (Takeda) to develop and commercialize ADCETRIS on a global basis. Under this collaboration, the company retains commercial rights for ADCETRIS in the United States and its territories and in Canada, and Takeda has commercial rights in the rest of the world. Beyond the company’s labeled indications, the company and Takeda have a development strategy for ADCETRIS evaluating its therapeutic potential in earlier lines of therapy for patients with Hodgkin lymphoma or mature T-cell lymphoma, including sALCL, and in other CD30-expressing malignancies. The company and Takeda are conducting three phase 3 clinical trials of ADCETRIS, such as ALCANZA, ECHELON-1 and ECHELON-2. All of these trials are being conducted under Special Protocol Assessment agreements with the FDA and pursuant to scientific advice from the European Medicines Agency. The company announced a planned phase 3 clinical trial that is being designed to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older acute myeloid leukemia (AML) patients. The company is also evaluating SGN-CD33A across multiple lines of therapy in patients with myeloid malignancies, including in ongoing and planned phase 1 and 2 clinical trials for newly diagnosed or relapsed AML patients and for newly diagnosed myelodysplastic syndrome (MDS) patients. In addition to ADCETRIS and SGN-CD33A, the company’s clinical-stage pipeline includes five other antibody-drug conjugate (ADC) programs consisting of SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME; and an immuno-oncology agent called SEA-CD40, which is based on the company’s sugar-engineered antibody (SEA) technology. In addition, the company has multiple pre-clinical and research-stage programs that employ its proprietary technologies, including SGN-CD19B and SGN-CD123A, two preclinical ADC product candidates that the company expects to enter clinical trials during 2016. The company has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc., a member of the Roche Group; GlaxoSmithKline LLC; Pfizer, Inc.; PSMA Development Company LLC, a subsidiary of Progenics Pharmaceuticals Inc.; and Takeda, as well as ADC co-development agreements with Agensys, Inc., an affiliate of Astellas Pharma, Inc. (Agensys); and Genmab A/S. The company also entered into a collaboration agreement in June 2015 with Unum Therapeutics, Inc. to develop and commercialize novel antibody-coupled T-cell receptor therapies incorporating the company’s antibodies for the treatment of cancer. SGN-CD33A SGN-CD33A is an ADC consisted of an anti-CD33 monoclonal antibody linked to a potent pyrrolobenzodiazepine (PBD) dimer using the company’s proprietary ADC technology, and is a product candidate being developed as a potential treatment of AML and MDS. SGN-CD33A targets CD33, a protein that is expressed on most AML cells. SGN-CD33A employs the company’s newest proprietary ADC technology. This technology includes a PBD dimer, which is a potent cell-killin
seattle genetics inc (SGT:Berlin)
21823 30th Drive SE
Bothell, WA 98021
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for SGT.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact SEATTLE GENETICS INC, please visit www.seattlegenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.